CERUS CORP (CERS) Fundamental Analysis & Valuation

NASDAQ:CERS • US1570851014

1.93 USD
-0.11 (-5.16%)
At close: Mar 6, 2026
1.95 USD
+0.02 (+1.04%)
After Hours: 3/6/2026, 8:05:54 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CERS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

CERS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 184 industry peers in the Health Care Equipment & Supplies industry. CERS has a bad profitability rating. Also its financial health evaluation is rather negative. CERS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

2

1. CERS Profitability Analysis

1.1 Basic Checks

  • CERS had negative earnings in the past year.
  • CERS had a positive operating cash flow in the past year.
  • CERS had negative earnings in each of the past 5 years.
  • CERS had negative operating cash flow in 4 of the past 5 years.
CERS Yearly Net Income VS EBIT VS OCF VS FCFCERS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • CERS's Return On Assets of -7.42% is fine compared to the rest of the industry. CERS outperforms 64.67% of its industry peers.
  • CERS has a Return On Equity (-25.97%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -7.42%
ROE -25.97%
ROIC N/A
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
CERS Yearly ROA, ROE, ROICCERS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • With a decent Gross Margin value of 60.50%, CERS is doing good in the industry, outperforming 62.50% of the companies in the same industry.
  • CERS's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for CERS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.5%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
CERS Yearly Profit, Operating, Gross MarginsCERS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. CERS Health Analysis

2.1 Basic Checks

  • CERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CERS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CERS Yearly Shares OutstandingCERS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
CERS Yearly Total Debt VS Total AssetsCERS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -4.15, we must say that CERS is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -4.15, CERS is not doing good in the industry: 67.39% of the companies in the same industry are doing better.
  • The Debt to FCF ratio of CERS is 505.38, which is on the high side as it means it would take CERS, 505.38 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 505.38, CERS is in the better half of the industry, outperforming 66.30% of the companies in the same industry.
  • CERS has a Debt/Equity ratio of 0.79. This is a neutral value indicating CERS is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.79, CERS is not doing good in the industry: 70.65% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF 505.38
Altman-Z -4.15
ROIC/WACCN/A
WACC10.78%
CERS Yearly LT Debt VS Equity VS FCFCERS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 1.89 indicates that CERS should not have too much problems paying its short term obligations.
  • The Current ratio of CERS (1.89) is worse than 65.76% of its industry peers.
  • CERS has a Quick Ratio of 1.29. This is a normal value and indicates that CERS is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.29, CERS is not doing good in the industry: 64.13% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.29
CERS Yearly Current Assets VS Current LiabilitesCERS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CERS Growth Analysis

3.1 Past

  • CERS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.27%, which is quite impressive.
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%13.66%

3.2 Future

  • The Earnings Per Share is expected to grow by 45.86% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, CERS will show a quite strong growth in Revenue. The Revenue will grow by 9.55% on average per year.
EPS Next Y49%
EPS Next 2Y45.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year9.5%
Revenue Next 2Y9.55%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

CERS Yearly Revenue VS EstimatesCERS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
CERS Yearly EPS VS EstimatesCERS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

2

4. CERS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CERS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CERS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CERS Price Earnings VS Forward Price EarningsCERS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

  • CERS's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CERS is cheaper than 66.30% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2206.75
EV/EBITDA N/A
CERS Per share dataCERS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CERS's earnings are expected to grow with 45.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.86%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CERS Dividend Analysis

5.1 Amount

  • No dividends for CERS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CERS Fundamentals: All Metrics, Ratios and Statistics

CERUS CORP

NASDAQ:CERS (3/6/2026, 8:05:54 PM)

After market: 1.95 +0.02 (+1.04%)

1.93

-0.11 (-5.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-02
Earnings (Next)04-29
Inst Owners70.5%
Inst Owner Change2.05%
Ins Owners2.94%
Ins Owner Change-0.45%
Market Cap370.73M
Revenue(TTM)N/A
Net Income(TTM)-15.96M
Analysts80
Price Target4.76 (146.63%)
Short Float %4.22%
Short Ratio5.61
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)46.52%
Min EPS beat(2)-6.95%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)28.92%
Min EPS beat(4)-6.95%
Max EPS beat(4)100%
EPS beat(8)6
Avg EPS beat(8)28.86%
EPS beat(12)7
Avg EPS beat(12)15.59%
EPS beat(16)11
Avg EPS beat(16)17.8%
Revenue beat(2)0
Avg Revenue beat(2)-5.23%
Min Revenue beat(2)-5.44%
Max Revenue beat(2)-5.03%
Revenue beat(4)1
Avg Revenue beat(4)-6.17%
Min Revenue beat(4)-14.57%
Max Revenue beat(4)0.34%
Revenue beat(8)1
Avg Revenue beat(8)-5.95%
Revenue beat(12)2
Avg Revenue beat(12)-6.05%
Revenue beat(16)6
Avg Revenue beat(16)-2.43%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)31.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.68%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.64
P/FCF 2206.75
P/OCF 103.96
P/B 6.03
P/tB 6.16
EV/EBITDA N/A
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)0
FCFY0.05%
OCF(TTM)0.02
OCFY0.96%
SpS1.18
BVpS0.32
TBVpS0.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.42%
ROE -25.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.5%
FCFM 0.07%
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
F-Score5
Asset Turnover1.05
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF 505.38
Debt/EBITDA N/A
Cap/Depr 248.94%
Cap/Sales 1.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.29
Altman-Z -4.15
F-Score5
WACC10.78%
ROIC/WACCN/A
Cap/Depr(3y)132.31%
Cap/Depr(5y)95.58%
Cap/Sales(3y)1.64%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y49%
EPS Next 2Y45.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%13.66%
Revenue Next Year9.5%
Revenue Next 2Y9.55%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year176.36%
EBIT Next 3Y54.48%
EBIT Next 5YN/A
FCF growth 1Y100.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y111.99%
OCF growth 3YN/A
OCF growth 5YN/A

CERUS CORP / CERS FAQ

Can you provide the ChartMill fundamental rating for CERUS CORP?

ChartMill assigns a fundamental rating of 2 / 10 to CERS.


Can you provide the valuation status for CERUS CORP?

ChartMill assigns a valuation rating of 2 / 10 to CERUS CORP (CERS). This can be considered as Overvalued.


How profitable is CERUS CORP (CERS) stock?

CERUS CORP (CERS) has a profitability rating of 2 / 10.


What is the financial health of CERUS CORP (CERS) stock?

The financial health rating of CERUS CORP (CERS) is 3 / 10.


Can you provide the expected EPS growth for CERS stock?

The Earnings per Share (EPS) of CERUS CORP (CERS) is expected to grow by 49% in the next year.